Impact of CD30 positivity on the Clinical Characteristics of Diffuse Large B-Cell Lymphoma

ATAKAN TEKİNALP

doi:10.56752/Mevmedsci.2025.91

ATAKAN TEKİNALP, ÖZCAN ÇENELİ, SİNAN DEMİRCİOĞLU, FAHRİYE KILINÇ, Hayrunnisa Pektaş Alpsoy

Year : 2025
Vol : 5
Issue : 2
Page : 65-71

DOI : 10.56752/Mevmedsci.2025.91

Objective: This study aims to analyze the relationship between CD30 positivity and clinical findings in patients diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL). Method: Patients diagnosed with DLBCL between January 2005 and November 2022 at Necmettin Erbakan University, Meram Faculty of Medicine, were evaluated. Their demographic and baseline laboratory data, disease stage, specific risk scores, and involved regions at diagnosis were recorded. Treatment regimens, response to therapy, post-diagnosis condition, stem cell transplantation history, and survival outcomes were assessed. Patients were classified into CD30(+) and CD30(-) groups based on the immunohistochemical staining of biopsy samples. The two groups were compared regarding clinical, laboratory, and disease-related features, as well as progression and survival outcomes. Results: Among 111 patients, 18 were CD30(+) and 93 were CD30(-). Median calcium levels were lower in the CD30(+) group (8.8 mmol/L vs. 9.2 mmol/L), with statistical significance (p=0.013). Other laboratory and clinical parameters showed no significant differences. The estimated median overall survival (OS) was lower in CD30(+) patients (36.9 months vs. 100.9 months), though the difference was not statistically significant (p=0.155). Similarly, median progression-free survival (PFS) was lower in CD30(+) patients (37 months vs. 100.9 months), also not statistically significant (p=0.849). Two-year OS rates were 70% for CD30(+) and 84% for CD30(-) patients, while three-year OS rates were 42% and 67%, respectively. Two-year PFS rates were 50% for CD30(+) and 80% for CD30(-) patients. Five-year PFS could not be calculated for CD30(+) patients but was 60% in the CD30(-) group. Conclusion: This study suggests that CD30 positivity does not have a significant impact on clinical characteristics or survival outcomes in patients with DLBCL.

Cite this Article As :

Description : Yazarların hiçbiri, bu makalede bahsedilen herhangi bir ürün, aygıt veya ilaç ile ilgili maddi çıkar ilişkisine sahip değildir. Araştırma, herhangi bir dış organizasyon tarafından desteklenmedi.Yazarlar çalışmanın birincil verilerine tam erişim izni vermek ve derginin talep ettiği takdirde verileri incelemesine izin vermeyi kabul etmektedirler. None of the authors, any product mentioned in this article, does not have a material interest in the device or drug. Research, not supported by any external organization. grant full access to the primary data and, if requested by the magazine they agree to allow the examination of data.

Impact of CD30 positivity on the Clinical Characteristics of Diffuse Large B-Cell Lymphoma, Research Article,
2025, Vol. 5 (2)

Received : 30.01.2025, Accepted : 24.07.2025 , Published Online : 08.08.2025